By Josh Beckerman
Day One Biopharmaceuticals' drug tovorafenib, or Ojemda, received accelerated approval from the U.S. Food and Drug Administration for patients with relapsed or refractory BRAF-altered pediatric low-grade glioma.
The agency said this represents the first approval of a systemic therapy for treatment of patients with pediatric LGG with BRAF rearrangements, including fusions. The FDA granted tovorafenib a priority review in October.
Day One Biopharmaceuticals shares rose 10%, to $16.90.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
04-23-24 1522ET